vs
Side-by-side financial comparison of IDEX Corporation (IEX) and Insulet Corporation (PODD). Click either name above to swap in a different company.
Insulet Corporation is the larger business by last-quarter revenue ($783.7M vs $398.4M, roughly 2.0× IDEX Corporation). IDEX Corporation runs the higher net margin — 30.1% vs 13.0%, a 17.2% gap on every dollar of revenue. On growth, Insulet Corporation posted the faster year-over-year revenue change (31.2% vs 16.7%). IDEX Corporation produced more free cash flow last quarter ($86.0M vs $48.2M). Over the past eight quarters, Insulet Corporation's revenue compounded faster (33.2% CAGR vs -29.4%).
IDEX can refer to several things, including:International Defence Exhibition, a biennial arms and defense technology sales exhibition IDEX Corporation, a publicly listed company that makes fluidics systems and specialty engineered products Ideanomics, a publicly traded company that trades under the IDEX ticker symbol.
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
IEX vs PODD — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $398.4M | $783.7M |
| Net Profit | $120.0M | $101.6M |
| Gross Margin | 99.9% | 72.6% |
| Operating Margin | 43.3% | 18.7% |
| Net Margin | 30.1% | 13.0% |
| Revenue YoY | 16.7% | 31.2% |
| Net Profit YoY | 25.7% | 0.9% |
| EPS (diluted) | $1.61 | $1.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 26 | $398.4M | — | ||
| Q1 26 | $407.7M | — | ||
| Q4 25 | $899.1M | $783.7M | ||
| Q3 25 | $878.7M | $706.3M | ||
| Q2 25 | $865.4M | $649.1M | ||
| Q1 25 | $814.3M | $569.0M | ||
| Q4 24 | $862.9M | $597.5M | ||
| Q3 24 | $798.2M | $543.9M |
| Q2 26 | $120.0M | — | ||
| Q1 26 | $128.3M | — | ||
| Q4 25 | $128.3M | $101.6M | ||
| Q3 25 | $127.8M | $87.6M | ||
| Q2 25 | $131.6M | $22.5M | ||
| Q1 25 | $95.5M | $35.4M | ||
| Q4 24 | $123.2M | $100.7M | ||
| Q3 24 | $119.1M | $77.5M |
| Q2 26 | 99.9% | — | ||
| Q1 26 | 94.9% | — | ||
| Q4 25 | 43.1% | 72.6% | ||
| Q3 25 | 44.5% | 72.2% | ||
| Q2 25 | 45.3% | 69.7% | ||
| Q1 25 | 45.3% | 71.9% | ||
| Q4 24 | 42.5% | 72.1% | ||
| Q3 24 | 44.3% | 69.3% |
| Q2 26 | 43.3% | — | ||
| Q1 26 | 45.0% | — | ||
| Q4 25 | 20.4% | 18.7% | ||
| Q3 25 | 21.1% | 16.7% | ||
| Q2 25 | 21.7% | 18.7% | ||
| Q1 25 | 17.4% | 15.6% | ||
| Q4 24 | 19.2% | 18.3% | ||
| Q3 24 | 21.0% | 16.2% |
| Q2 26 | 30.1% | — | ||
| Q1 26 | 31.5% | — | ||
| Q4 25 | 14.3% | 13.0% | ||
| Q3 25 | 14.5% | 12.4% | ||
| Q2 25 | 15.2% | 3.5% | ||
| Q1 25 | 11.7% | 6.2% | ||
| Q4 24 | 14.3% | 16.9% | ||
| Q3 24 | 14.9% | 14.2% |
| Q2 26 | $1.61 | — | ||
| Q1 26 | $1.71 | — | ||
| Q4 25 | $1.71 | $1.42 | ||
| Q3 25 | $1.70 | $1.24 | ||
| Q2 25 | $1.74 | $0.32 | ||
| Q1 25 | $1.26 | $0.50 | ||
| Q4 24 | $1.61 | $1.38 | ||
| Q3 24 | $1.57 | $1.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $586.2M | — |
| Total DebtLower is stronger | — | $930.8M |
| Stockholders' EquityBook value | $4.0B | $1.5B |
| Total Assets | $6.9B | $3.2B |
| Debt / EquityLower = less leverage | — | 0.61× |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | $586.2M | — | ||
| Q1 26 | $580.0M | — | ||
| Q4 25 | $580.0M | — | ||
| Q3 25 | $593.8M | — | ||
| Q2 25 | $568.2M | — | ||
| Q1 25 | $594.1M | — | ||
| Q4 24 | $620.8M | — | ||
| Q3 24 | $633.2M | — |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $1.8B | $930.8M | ||
| Q3 25 | $1.9B | $934.9M | ||
| Q2 25 | $1.9B | $939.0M | ||
| Q1 25 | $2.0B | $1.6B | ||
| Q4 24 | $2.0B | $1.3B | ||
| Q3 24 | $2.1B | $1.4B |
| Q2 26 | $4.0B | — | ||
| Q1 26 | $4.0B | — | ||
| Q4 25 | $4.0B | $1.5B | ||
| Q3 25 | $4.0B | $1.4B | ||
| Q2 25 | $4.0B | $1.5B | ||
| Q1 25 | $3.9B | $1.3B | ||
| Q4 24 | $3.8B | $1.2B | ||
| Q3 24 | $3.8B | $1.1B |
| Q2 26 | $6.9B | — | ||
| Q1 26 | $6.9B | — | ||
| Q4 25 | $6.9B | $3.2B | ||
| Q3 25 | $7.0B | $3.0B | ||
| Q2 25 | $6.9B | $3.5B | ||
| Q1 25 | $6.8B | $3.5B | ||
| Q4 24 | $6.7B | $3.1B | ||
| Q3 24 | $7.0B | $3.0B |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 0.45× | 0.61× | ||
| Q3 25 | 0.48× | 0.68× | ||
| Q2 25 | 0.46× | 0.64× | ||
| Q1 25 | 0.50× | 1.21× | ||
| Q4 24 | 0.52× | 1.07× | ||
| Q3 24 | 0.55× | 1.21× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $183.3M |
| Free Cash FlowOCF − Capex | $86.0M | $48.2M |
| FCF MarginFCF / Revenue | 21.6% | 6.2% |
| Capex IntensityCapex / Revenue | 4.4% | 17.2% |
| Cash ConversionOCF / Net Profit | — | 1.80× |
| TTM Free Cash FlowTrailing 4 quarters | $654.3M | $377.7M |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $209.5M | $183.3M | ||
| Q3 25 | $203.5M | $125.7M | ||
| Q2 25 | $161.7M | $196.5M | ||
| Q1 25 | $105.7M | $63.8M | ||
| Q4 24 | $172.6M | $147.7M | ||
| Q3 24 | $205.3M | $98.5M |
| Q2 26 | $86.0M | — | ||
| Q1 26 | $189.8M | — | ||
| Q4 25 | $189.8M | $48.2M | ||
| Q3 25 | $188.7M | $100.1M | ||
| Q2 25 | $146.9M | $177.9M | ||
| Q1 25 | $91.4M | $51.5M | ||
| Q4 24 | $157.1M | $94.1M | ||
| Q3 24 | $191.6M | $71.8M |
| Q2 26 | 21.6% | — | ||
| Q1 26 | 46.6% | — | ||
| Q4 25 | 21.1% | 6.2% | ||
| Q3 25 | 21.5% | 14.2% | ||
| Q2 25 | 17.0% | 27.4% | ||
| Q1 25 | 11.2% | 9.1% | ||
| Q4 24 | 18.2% | 15.7% | ||
| Q3 24 | 24.0% | 13.2% |
| Q2 26 | 4.4% | — | ||
| Q1 26 | 15.6% | — | ||
| Q4 25 | 2.2% | 17.2% | ||
| Q3 25 | 1.7% | 3.6% | ||
| Q2 25 | 1.7% | 2.9% | ||
| Q1 25 | 1.8% | 2.2% | ||
| Q4 24 | 1.8% | 9.0% | ||
| Q3 24 | 1.7% | 4.9% |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 1.63× | 1.80× | ||
| Q3 25 | 1.59× | 1.43× | ||
| Q2 25 | 1.23× | 8.73× | ||
| Q1 25 | 1.11× | 1.80× | ||
| Q4 24 | 1.40× | 1.47× | ||
| Q3 24 | 1.72× | 1.27× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IEX
Segment breakdown not available.
PODD
| U.S.Omnipod | $567.8M | 72% |
| International Omnipod | $214.0M | 27% |
| Drug Delivery | $1.9M | 0% |
